Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review

Rákkutatás · Acute lymphoblastic leukemia

NGS promises significant benefits in NHL diagnosis and management in developing countries.

Non‑Hodgkin lymphoma (NHL) is the most prevalent hematological malignancy worldwide and accounts for approximately 3% of all cancer cases and fatalities. Next‑generation sequencing (NGS) has advanced molecular diagnosis and targeted treatment in developed countries. However, developing countries face barriers like limited infrastructure, funding, and expertise, hindering wide NGS adoption. This narrative review evaluates the progress, challenges, and feasibility of using NGS for NHL diagnosis in developing countries. NGS has improved NHL subclassification accuracy and identified clinically relevant mutations, enabling personalized therapies. Studies from China, India, and South Africa demonstrate successful implementation of panel‑based NGS strategies. Despite this, challenges persist, including high costs, lack of standardized protocols, infrastructural deficits, and workforce shortages, limiting broader utilization in resource‑limited settings. NGS promises significant benefits in NHL diagnosis and management in developing countries. Overcoming financial, technical, and training barriers through targeted policies, funding, and international cooperation is crucial to harnessing its full potential. With ongoing advancements, NGS is poised to become a crucial tool for diagnosis and guiding therapy worldwide, including in resource‑limited settings.

The claim highlights the potential of next‑generation sequencing to transform the diagnostic landscape for non‑Hodgkin lymphoma in resource‑limited settings, thereby improving patient outcomes through more accurate sub‑classification and personalized treatment.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek